top of page
Leveraging Large Quantitative Models and other advanced AI technologies to design and rapidly screen potential new drug compounds for Parkinson's Disease
We are very excited to announce a new drug discovery project in our lab aimed at accelerating the development of innovative therapies for Parkinson’s disease, which runs in collaboration with CD3 at KU Leuven, SandboxAQ, and The Michael J. Fox Foundation for Parkinson’s disease research.
By harnessing cutting-edge AI technology at SandboxAQ and our team’s expertise in lysosomal transporters ATP10B and ATP13A2, we’re working to identify novel drug compounds with the potential to make a meaningful impact for those living with this complex condition.
Together, we’re committed to pushing the boundaries of what’s possible in Parkinson’s disease drug discovery research.
bottom of page